

(2017 DX18) Evaluation of Efficacy and Tolerability of Sc IFN Beta 1-a Given Three Times per Week in an Older Multiple Sclerosis Population

Bianca Weinstock-Guttman, MD1,2,3, Caila B Vaughn, PhD, MPH1,2,3, Katelyn S. Kavak, MS1,2,3, Barbara E. Teter, PhD, MPH1, S. Ahmed Sanai, MD3, Andrew Goodman, MD1,4, Patricia K Coyle, MD1,5, Lauren Krupp, MD1,6, Malcolm Gottesman, MD1,7 and Keith R Edwards, MD1,8, (1)New York State Multiple Sclerosis Consortium, Buffalo, NY, (2)Jacobs MS Center of Treatment and Research, Buffalo, NY, (3)Department of Neurology, University at Buffalo, Buffalo, NY, (4)Neurology, University of Rochester, Rochester, NY, (5)Stony Brook University, Stony Brook, NY, (6)NYU Langone Medical Center, New York, NY, (7)Winthrop Comprehensive MS Care Center, Mineola, NY, (8)MS Center of Northeastern New York, Latham, NY

(2017 DX39) Monthly 3T MRI in MS Patients Switched from Natalizumab to Teriflunomide in a Controlled, Prospective Study

Keith R Edwards, MD1, Stanley Cohan, MD, PhD2, Lore Garten, MD, Ph. D.1, James Thomas, M.D.3, Kyle E Smoot, MD2, Kiren Kresa-Reahl, MD2, Judy O'Connor, BSW, CCRC1, Tiffany Gervasi, Clinical Research Coordinator2, Chiayi Chen, Ph.D.2, Jessica Siuta, BSMT, ASCP, Clinical Research Coordinator1 and Vineetha Kamath, BS1, (1)MS Center of Northeastern New York, Latham, NY, (2)Providence Multiple Sclerosis Center, Portland, OR, (3)Radiology, Community Care Physicians, P.C., Latham, NY

(2017 DX52) Teriflunomide Real-World Outcomes from the US Cohort of the Phase 4 Teri-PRO Study

Patricia K Coyle, MD1, Bhupendra Khatri, MD2, Keith R Edwards, MD3, Steve Cavalier, MD4, Pascal Rufi, MD5, Karthinathan Thangavelu, PhD4, Myriam Benamor, MD5 and Ralf Gold, MD6, (1)Stony Brook University, Stony Brook, NY, (2)The Regional MS Center, Center for Neurological Disorders at Wheaton Franciscan Healthcare, Milwaukee, WI, (3)Multiple Sclerosis Center of Northeastern New York, Latham, NY, (4)Sanofi Genzyme, Cambridge, MA, (5)Sanofi Genzyme, Chilly-Mazarin, France, (6)St Josef Hospital, Ruhr University Bochum, Bochum, Germany

(2017 QL04) Outcomes in the African-American Subpopulation from the Phase 4 Teri-PRO Study of Teriflunomide

Annette Okai, MD1, Bhupendra Khatri, MD2, Keith R Edwards, MD3, Steve Cavalier, MD4, Pascal Rufi, MD5, Soman Chowdhury, MSc6, Myriam Benamor, MD5, Ralf Gold, MD7 and Patricia K Coyle, MD8, (1)Multiple Sclerosis Treatment Center of Dallas, Dallas, TX, (2)The Regional MS Center, Center for Neurological Disorders at Wheaton Franciscan Healthcare, Milwaukee, WI, (3)Multiple Sclerosis Center of Northeastern New York, Latham, NY, (4)Sanofi Genzyme, Cambridge, MA, (5)Sanofi Genzyme, Chilly-Mazarin, France, (6)Cytel Statistical Software and Services,